Program
D-2570
A development code. Also written as “D-2570 Tablet”, “D-2570 Dose 1” and “D-2570 Dose 2”.
Its studies are mostly in Psoriasis · Renal Insufficiency · Colitis, Ulcerative · Vitiligo · Lupus Erythematosus, Systemic, led by InventisBio.
Furthest: phase 3, since Aug 12, 202513 company-led studies, 11 open or runningNext primary completion: Nov 21, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InventisBio | 1311 open or running | phase 3since Aug 12, 2025 | Jan 30, 2024 | Nov 21, 2026phase 1 · NCT07715175 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2024First study: phase 2 study in Plaque PsoriasisFirst studyNCT06278350 · 161 enrolled · China
- Nov 4, 2024Phase 1 study in HealthyNCT07275775 · 100 enrolled · China
- May 19, 2025Phase 2 study in Colitis, UlcerativeNCT07035041 · 120 enrolled · China
- Aug 12, 2025Phase 3 study in Plaque PsoriasisNCT07130604 · 390 planned · China
- Nov 12, 2025Phase 1 study in Healthy VolunteerNCT07270783 · 36 enrolled · United States
- Dec 12, 2025Phase 3 study in Plaque PsoriasisNCT07326813 · 477 planned · China
- Dec 16, 20252 phase 2 studiesNCT07311200, NCT07315061
- Mar 18, 2026Phase 2 study in PsoriasisNCT07489885 · 75 planned · United States
- May 28, 2026Phase 2 study in VitiligoNCT07625891 · 160 planned · China
- Jul 13, 20262 phase 1 studiesNCT07715175, NCT07715149
- Sep 22, 2026Phase 1 study in Healthy SubjectsNCT07875842 · 60 planned · China
Ahead
- Nov 21, 2026Primary completion: phase 1 study in Renal InsufficiencyNCT07715175
- Dec 31, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07875842
- Jul 12, 2027Primary completion: phase 3 study in Plaque PsoriasisNCT07326813
- Jul 28, 2027Primary completion: phase 3 study in Plaque PsoriasisNCT07130604
TargetBeta
TYK2 →read by rule
“D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain”study text, by rule · the study
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| deucravacitinibrule | Bristol-Myers Squibb | phase 4 | 60 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| TQH3906 | Sino Biopharmaceutical | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07875842Healthy Subjects · China | 1 | Not yet recruiting | Dec 31, 2026 | 60 |
| NCT07715175Renal Insufficiency · China | 1 | Recruiting | Nov 21, 2026 | 40 |
| NCT07715149Healthy Adult Participants · China | 1 | Recruiting | Oct 31, 2026 | 24 |
| NCT07625891Vitiligo · China | 2 | Recruiting | Nov 2027 | 160 |
| NCT07489885Psoriasis · United States | 2 | Recruiting | Aug 2027 | 75 |
| NCT07315061Arthritis, Psoriatic · China | 2 | Recruiting | Aug 15, 2027 | 222 |
| NCT07311200Active Systemic Lupus Erythematosus · China | 2 | Recruiting | Aug 31, 2028 | 120 |
| NCT07326813Plaque Psoriasis · China | 3 | Recruiting | Jul 12, 2027 | 477 |
| NCT07270783Healthy Volunteer · United States | 1 | Active, not recruiting | Jun 25, 2026 | 36 |
| NCT07130604Plaque Psoriasis · China | 3 | Recruiting | Jul 28, 2027 | 390 |
| NCT07035041Colitis, Ulcerative · China | 2 | Active, not recruiting | Jul 30, 2026 | 120 |
| NCT07275775Healthy · China | 1 | Completed | Jun 23, 2025 | 100 |
| NCT06278350Plaque Psoriasis · China | 2 | Completed | Nov 1, 2024 | 161 |
How it is read
Names in the registry
- “D-2570”, 10 entries
- “D-2570 Tablet”, 2 entries
- “D-2570 Dose 1”, 1 entry
- “D-2570 Dose 2”, 1 entry
- “D-2570 Dose 3”, 1 entry
Codes read as this program: D2570.
Conditions, from the studies’ own filings
- Psoriasis, 4 studies
- Renal Insufficiency, 1 study
- Colitis, Ulcerative, 1 study
- Vitiligo, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.